Infliximab has high aspirations for rheumatoid arthritis

Data from the ASPIRE and START studies presented at the European League Against Rheumatism (EULAR) annual meeting [Vienna, Austria; June 2005] showed that infliximab [Remicade] is a safe and effective treatment for rheumatoid arthritis (RA) when given in combination with methotrexate. In the ASPIRE study, patients with early RA had delayed radiographic progression and improvements in physical function during treatment with infliximab plus methotrexate. Patients in the START study receiving infliximab plus methotrexate experienced disease remission and improvements in quality of life (QOL).